Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Giorgio Mustacchi. (2021) Cost/benefit evaluations in low-middle/upper-middle income countries: biases about “out of pocket money”. Current Medical Research and Opinion 37:5, pages 819-820.
Read now
Read now
Reshma L Mahtani & Charles L Vogel. (2019) Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. Cancer Management and Research 11, pages 513-524.
Read now
Read now
Henry W. C. Leung, Agnes L. F. Chan, Chih-Hsin Muo & John Hang Leung. (2018) Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer. Expert Review of Pharmacoeconomics & Outcomes Research 18:2, pages 207-213.
Read now
Read now
Articles from other publishers (2)
Ronnachai Kongsakon, Surasit Lochid-amnuay, Nattiya Kapol & Oraluck Pattanaprateep. (2019) From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand. Value in Health Regional Issues 18, pages 47-53.
Crossref
Crossref
Ana Voda & Ionel Bostan. (2018) Public Health Care Financing and the Costs of Cancer Care: A Cross-National Analysis. Cancers 10:4, pages 117.
Crossref
Crossref